Dysferlinopathy: a new myopathy

被引:5
|
作者
Serratrice, G
Pellissier, JF
N'Guyen, V
Attarian, S
Pouget, J
机构
来源
关键词
muscular dystrophies; muscle proteins; gene expression;
D O I
10.1016/S0001-4079(19)34247-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the past 10 years, the impact of modern microscopic pathology and molecular genetics on the knowledge of myopathies has been enormous. Dysferlinopathy is a good example. Dysferlin is a surface membrane protein without homology with known mammalian protein excepted otoferlin. It is encoded by a gene on chromosome 2. Miyoshi myopathy and limb girdle muscular dystrophy 2B have been reported to arise from defects in the same genetic locus (chromosome 2p 13). Some personal different examples are presented with typical features, high level of creatine kinase. Gene mutations, immunoblot and immunohistochemestry allow the diagnosis. Three clinical phenotypes are separed : distal myopathy, proximal myopathy, entire lower limbs posterior compartment amyotrophy. Structural changes are mild. Inflammation is not unusual and leads to the diagnosis of polymyositis. There are no correlation genotype-phenotype.
引用
收藏
页码:1025 / 1034
页数:10
相关论文
共 50 条
  • [21] Respiratory dysfunction of dysferlinopathy
    Nishikawa, A.
    Mori-Yoshimura, M.
    Hayashi, Y.
    Oya, Y.
    Nishino, I.
    Murata, M.
    NEUROMUSCULAR DISORDERS, 2012, 22 (9-10) : 895 - 895
  • [22] Dysferlinopathy in two siblings
    Brabeck, C
    Neu, I
    Kress, W
    Bornemann, A
    ACTA NEUROPATHOLOGICA, 2001, 102 (05) : 520 - 520
  • [23] SERCAI and calsequestrin storage myopathy: a new surplus protein myopathy
    Tomelleri, Giuliano
    Palmucci, Laura
    Tonin, Paola
    Mongini, Tiziana
    Marini, Matteo
    L'Erario, Roberto
    Rizzuto, Nicolo
    Vattemi, Gaetano
    BRAIN, 2006, 129 : 2085 - 2092
  • [24] Clinical heterogeneity in dysferlinopathy
    Ueyama, H
    Kumamoto, T
    Horinouchi, H
    Fujimoto, S
    Aono, H
    Tsuda, T
    INTERNAL MEDICINE, 2002, 41 (07) : 532 - 536
  • [25] North Star Assessment for dysferlinopathy: Longitudinal performance in the clinical outcome study of dysferlinopathy
    James, M.
    Mayhew, A.
    Eagle, M.
    Lofra, R. Muni
    Maron, E.
    Gee, R.
    Harman, M.
    Duong, T.
    Vandevelde, B.
    Siener, C.
    Thiele, S.
    Mendez, J.
    Canal, A.
    Sakamoto, C.
    Holsten, S.
    Pedrosa-Hernandez, I.
    Semplicini, C.
    Lowes, L.
    Bushby, K.
    Straub, V.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S145 - S145
  • [26] Clinical Outcome Study of Dysferlinopathy: what are the best outcome measures for dysferlinopathy patients?
    James, M. K.
    Jacobs, M.
    Mayhew, A.
    Feng, J.
    Spuler, S.
    Day, J. W.
    Jones, K. J.
    Bharucha-Goebel, D. X.
    Salort-Campana, E.
    Pestronk, A.
    Walter, M. C.
    Paradas, C.
    Stojkovic, T.
    Mori-Yoshimura, M.
    Bravver, E.
    Manera, J. Diaz
    Pegoraro, E.
    Mendell, J. R.
    Bushby, K.
    Straub, V.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S6 - S6
  • [27] Myopathy Five New Things
    Oskarsson, Bjoern
    NEUROLOGY, 2011, 76 (07) : S14 - S19
  • [28] New myotubular myopathy classification
    Lilien, C.
    Annoussamy, M.
    Gidaro, T.
    Gargaun, E.
    Che, V.
    Schara, U.
    D'Amico, A.
    Daron, A.
    Cuisset, J.
    Mayer, M.
    Hernandez, A.
    Vuillerot, C.
    Fontaine, S.
    deLattre, C.
    Bellance, R.
    Biancalana, V.
    Buj-Bello, A.
    Hogrel, J. Y.
    Landy, H.
    Servais, L.
    NEUROMUSCULAR DISORDERS, 2017, 27 : S169 - S169
  • [29] METHIONINEMIA AND MYOPATHY - A NEW DISORDER
    GAULL, GE
    BENDER, AN
    VULOVIC, D
    TALLAN, HH
    SCHAFFNER, F
    ANNALS OF NEUROLOGY, 1981, 9 (05) : 423 - 432
  • [30] A NEW MYOPATHY WITH TUBULOMEMBRANOUS INCLUSIONS
    FUKUHARA, N
    KUMAMOTO, T
    HIRAHARA, H
    TSUBAKI, T
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1981, 50 (01) : 95 - 107